WuXi Biologics to Acquire Biologics DS and DP Manufacturing Facilities from Pfizer China

HANGZHOU, China, March 16, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has entered into an equity agreement with Pfizer China ("Pfizer") to acquire its state-of-the-art...

from PR Newswire: https://ift.tt/3bUPS7X